Functional Mitral Valve Regurgitation (FMR) is a debilitating heart condition that affects millions of people worldwide. Current surgical procedures are difficult to perform, pose significant risks, and lead to a high rate of reoccurrence. Only about 6% of patients eligible for surgical intervention receive it today.1
Mardil’s revolutionary technology, the VenTouch™ System, offers a new therapy that addresses the underlying root cause mechanism of FMR through a minimally invasive procedure that’s been developed by world leading heart surgeons. Throughout, our emphasis has been on engineering safety and simplicity into an optimally effective technology. The company estimates the market potential to be $1.4 billion in the U.S. alone.
1. Dymedex Consulting, Market Opportunity Assessment performed for Mardil Medical,
May 2011. Dymedex.com >
Caution: Investigational device limited by Federal (USA) Law to investigational use